stock.name

Bristol-Myers Squibb Co.

BMY

Market Cap$100.83B
Close$

Compare Bristol-Myers Squibb

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Bristol-Myers Squibb Co.Bristol-Myers Squibb Co.12.64.56%27%2.31.4
marketMarket Avg49.51.28%13%6.20.1
HealthcareHealthcare Avg31.91.26%18%7.50.9

Earnings Call Q4 2023

February 2, 2024 - AI Summary

Q4 2023 was a strong quarter for Bristol-Myers Squibb (BMS), with 9% growth and nearly $10 billion in revenue, driven by sales momentum in their inline and new product portfolio.
BMS expects to grow their business in 2024, with revenues projected to increase in the low-single digit range. They anticipate continued strong demand for key products like Opdivo and Eliquis.
The company is focused on executing their strategy to navigate LOEs (loss of exclusivity) and maximize the potential of their growth portfolio. They aim to minimize the transition period and accelerate R&D programs to deliver sustainable top-tier growth in the latter part of the decade.
BMS achieved important pipeline milestones and made several key business development transactions to strengthen their growth profile. This includes acquisitions such as Karuna Therapeutics and RayzeBio, which bring transformative medicines and radiopharmaceutical assets to their portfolio.
The launch of new products, including Camzyos, Sotyktu, Reblozyl, and Opdualag, has shown positive performance and contributed to the growth of BMS's portfolio. They are investing in these brands to drive further growth and market share.
BMS plans to repay approximately $10 billion of debt over the next two years to improve their leverage profile. They have a strong financial position and continue to generate significant cash flows from operations. Overall, the earnings call highlighted BMS's strong performance, focus on execution, and strategic initiatives to drive growth and navigate challenges. The company's expanding portfolio, pipeline, and financial strength provide opportunities for future success.
$57.50

Target Price by Analysts

12% upsideBristol-Myers Squibb Target Price DetailsTarget Price
$56.05

Current Fair Value

9.2% upside

Undervalued by 9.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$100.83 Billion
Enterprise Value$128.32 Billion
Dividend Yield$2.2741 (4.56%)
Earnings per Share$3.86
Beta0.0
Outstanding Shares2,022,193,411
Avg 30 Day Volume15,915,239

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio12.56
PEG-97.71
Price to Sales2.33
Price to Book Ratio3.67
Enterprise Value to Revenue2.85
Enterprise Value to EBIT15.66
Enterprise Value to Net Income15
Total Debt to Enterprise0.31
Debt to Equity1.35

Revenue Sources

No data

ESG Score

No data

About Bristol-Myers Squibb Co.

30,250 employees
CEO: Giovanni Caforio

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.